Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2018 | Supporting innovation for better, more effective Alzheimer’s treatments

Susan Catalano • 22 Jul 2018
AAIC 2018
Alzheimer’s Disease Dementia

Current treatments for Alzheimer’s disease are currently not effective enough to have a lasting effect on the patient’s health, which is why Susan Catalano, PhD, of Cognition Therapeutics Inc., Pittsburgh, PA, tells us about the need for new, innovative approaches for treatment. Dr Catalano mentions several institutions that are collaborating on the fight against Alzheimer’s and believes that this will lead to a promising future for Alzheimer’s therapy. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2018, held in Chicago, IL.

More from Susan Catalano

CT1812: exciting preliminary results
1:38
CT1812: exciting preliminary results
Susan Catalano • 27 Oct 2020
A673T mutation lowers Aβ oligomer binding affinity: Alzheimer’s disease protective mechanism
3:00
A673T mutation lowers Aβ oligomer binding affinity: Alzheimer’s disease protective mechanism
Susan Catalano • 27 Oct 2020
Therapeutics designed to mimic protective mutations for Alzheimer's disease
1:20
Therapeutics designed to mimic protective mutations for Alzheimer's disease
Susan Catalano • 27 Oct 2020
Synaptoprotective Sigma-2 antagonists for Alzheimer's
1:47
Synaptoprotective Sigma-2 antagonists for Alzheimer's
Susan Catalano • 22 Jul 2018

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals